These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Corneal Collagen Cross-Linking With Photoactivated Chromophore for Infectious Keratitis After Penetrating Keratoplasty.
    Author: Ozbek-Uzman S, Yalniz-Akkaya Z, Burcu A.
    Journal: Cornea; 2020 Mar; 39(3):283-289. PubMed ID: 31764287.
    Abstract:
    PURPOSE: To evaluate the efficacy and safety of corneal collagen cross-linking with photoactivated chromophore (PACK-CXL) plus medical treatment in comparison with the non-CXL group in the management of graft infections after penetrating keratoplasty. METHODS: Forty eyes of 40 patients, 18 eyes in the PACK-CXL group and 22 eyes in the non-CXL group, with graft infections were retrospectively reviewed. Patients with microbial keratitis who were resistant to medical treatment for at least 1 week were treated with PACK-CXL in conjunction with medical treatment. The non-CXL group received only medical treatment. RESULTS: The median (interquartile range) size of the infiltrate was 11 (3-12.7) versus 7.5 (3.5-12.7) mm (P = 0.37), the epithelization time was 3 (2.7-5) versus 6 (3-11.2) days (P = 0.06), the complete healing time was 23.5 (17.7-33.5) versus 34 (27.7-41.2) days (P = 0.02), and the best-corrected distance visual acuity was 2.5 (0.5-3) versus 2.0 (0.9-3) logarithm of the minimum angle of resolution (P = 0.79) at presentation and 1 (0.3-3) versus 3 (1-3) logarithm of the minimum angle of resolution (P = 0.19) at the final visit for the PACK-CXL and non-CXL groups, respectively. Resolution of infiltrates was observed in 83.3% and 68.2% of cases in the PACK-CXL and non-CXL groups, respectively (P = 0.28). Graft failure was observed in 5 (27.8%) and 12 (54.5%) patients in the PACK-CXL and non-CXL groups, respectively (P = 0.08). CONCLUSIONS: PACK-CXL appears to be a promising adjuvant procedure in the management of resistant graft infections by reducing both the duration required for complete healing and rates of graft failure.
    [Abstract] [Full Text] [Related] [New Search]